Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza
Cocrystal Pharma announced that its novel direct-acting antivirals demonstrate pan-viral activity against hantavirus, bunyavirus, and influenza in early-stage in vitro studies. The compounds target the L-protein of the viral replication enzyme, showing superior potency with IC50 values below 50 nM against hantaan virus.
Key figures
- Ic50 potency
- <50 nM
- Target viruses
- hantavirus, bunyavirus, influenza
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.